Santhera reports preliminary key financial figures for 2014
(Thomson Reuters ONE) -
Santhera Pharmaceuticals Holding AG /
Santhera reports preliminary key financial figures for 2014
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Liestal, Switzerland, January 23, 2015 - Santhera Pharmaceuticals (SIX: SANN)
today announced preliminary, unaudited key financial figures for 2014. For the
reporting period, the Company increased revenues and made significant progress
in all product development programs.
* In 2014, the Company reported increased net sales of CHF 2.6 million (2013:
CHF 1.3 million) from sales of Raxone(®). These sales originated from
international Named Patient Programs as well as first product sales for
patients with Leber's Hereditary Optic Neuropathy (LHON) under the temporary
authorization for use (ATUc) granted in France. This ATUc was recently
renewed for 2015.
* Together with financing in the aggregate gross amount of CHF 15.7 million
Santhera had CHF 17.4 million in cash and cash equivalents by end of 2014
(December 31, 2013: CHF 5.0 million).
* As a result of the financings and option exercises in 2014, and with
effective date January 28, 2015, the Company's outstanding shares entered
into the commercial register will amount to 4,974,492.
Thomas Meier, PhD, Chief Executive Officer of Santhera commented: "We are very
excited about Santhera's development last year. Financially, we benefitted from
income from share placements and increasing revenues from product sales. We are
particularly pleased about the product acceptance and enrolment of LHON patients
under the French ATUc protocol for Raxone. The Company made tremendous progress
in all development and regulatory activities.
In the first half of 2015, we are expecting the opinion from the Committee for
Medicinal Products for Human Use (CHMP) on our European marketing authorization
application for Raxone in LHON which could become the first product authorized
for the treatment of this disease. Based on the successful outcome of the
Phase III trial in Duchenne Muscular Dystrophy, we also currently prepare for
regulatory filings for this indication both in the US and Europe."
Upcoming corporate events:
* Release of the audited financial results for 2014 on April 14, 2015
* Annual Shareholder's Meeting on May 20, 2015
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of orphan mitochondrial and neuromuscular diseases.
Santhera develops Catena(®)/Raxone(®) as treatment for patients with Leber's
Hereditary Optic Neuropathy (LHON), Duchenne Muscular Dystrophy (DMD) and
Primary Progressive Multiple Sclerosis (PPMS) and omigapil for Congenital
Muscular Dystrophies (CMD), all areas of high unmet medical need for which no
therapies are currently available. For further information, please visit the
Company's website www.santhera.com.
Raxone(®) and Catena(®) are trademarks of Santhera Pharmaceuticals.
For further information, contact:
Thomas Meier, Chief Executive Officer
Phone +41 61 906 89 64
thomas.meier(at)santhera.com
US Investor contact:
Andrew McDonald
LifeSci Advisors, LLC
Phone +1 646 597 6979
andrew(at)lifesciadvisors.com
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.
# # #
News release Prelim:
http://hugin.info/137261/R/1889036/668601.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via GlobeNewswire
[HUG#1889036]
Unternehmensinformation / Kurzprofil:
Datum: 23.01.2015 - 07:15 Uhr
Sprache: Deutsch
News-ID 366479
Anzahl Zeichen: 5270
contact information:
Town:
Liestal
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 154 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Santhera reports preliminary key financial figures for 2014"
steht unter der journalistisch-redaktionellen Verantwortung von
Santhera Pharmaceuticals Holding AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
